Aplex Bio

About:

Developing a next-generation Hyperplexed PCR technology

Twitter/X: aplexbio

Description:

APLEX Bio is a Swedish start-up founded in 2020 developing and commercializing a next-generation hyperplexed molecular detection technology for analysis of massive numbers of biomarkers both in-vitro and in-situ. The technology enables applications from research to mass-scale in-vitro diagnostics (IVD) and precision diagnostics. APLEX Bio is based in Stockholm at the Karolinska Institute (KI) campus and is part of KI Innovations.

Total Funding Amount:

14.2M SEK

Headquarters Location:

Solna, Stockholms Lan, Sweden

Founded Date:

2020-01-01

Contact Email:

hi(AT)aplex.bio

Founders:

Umear Naseem

Number of Employees:

1-10

Last Funding Date:

2021-12-31

IPO Status:

Private

Industries: